StockNews.AI
EXAS
StockNews.AI
182 days

U.S. Patent Trial and Appeal Board Institutes Inter Partes Review Based on Geneoscopy's Petition Challenging Validity of a Second Patent Asserted by Exact Sciences

1. Geneoscopy's review may challenge Exact Sciences' patent integrity. 2. Patent disputes could impact EXAS's market position.

2m saved
Insight
Article

FAQ

Why Bearish?

Patent challenges can diminish investor confidence; past patent disputes have led to stock declines.

How important is it?

The outcome of this review is critical as it affects EXAS's intellectual property.

Why Short Term?

Immediate market reaction is likely, but long-term effects depend on the outcome of the review.

Related Companies

EXASGENO
ST. LOUIS--(BUSINESS WIRE)--Geneoscopy announced that the U.S. Patent Trial and Appeal Board instituted inter partes review of U.S. Patent No. 11,970,746 owned by Exact Sciences.

Related News